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Objective: Scoliosis surgery involves major blood loss and frequently requires blood transfu-
sion. The cost and risks involved in using allogeneic blood have motivated investigation of
methods capable of reducing patients’ bleeding during operations. One of these methods is
to  use antiﬁbrinolytic drugs, and tranexamic acid is among these. The aim of this study was
to  assess the use of this drug for controlling bleeding in surgery to treat idiopathic scoliosis.
Methods: This was a retrospective study in which the medical ﬁles of 40 patients who under-
went thoracolumbar arthrodesis by means of a posterior route were analyzed. Of these cases,
21  used tranexamic acid and were placed in the test group. The others were placed in the
control group. The mean volumes of bleeding during and after the operation and the need
for  blood transfusion were compared between the two groups.
Results: The group that used tranexamic acid had signiﬁcantly less bleeding during the
operation than the control group. There was no signiﬁcant difference between the groups
regarding postoperative bleeding and the need for blood transfusion.
Conclusions: Tranexamic acid was effective in reducing bleeding during the operation, as
demonstrated in other studies. The correlation between its use and the reduction in the need
for  blood transfusion is multifactorial and could not be established in this study. We  believe
that tranexamic acid may be a useful resource and that it deserves greater attention in
randomized double-blind prospective series, with proper control over variables that directly
inﬂuence blood loss.
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Uso  do  ácido  tranexâmico  no  controle  do  sangramento  em  cirurgias  de
escoliose  toracolombar  com  instrumentac¸ão  posterior
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Objetivo: A cirurgia de escoliose envolve elevada perda sanguínea e necessita frequente-
mente de hemotransfusão. O custo e os riscos envolvidos no uso do sangue alogênico
têm motivado pesquisas de métodos capazes de reduzir o sangramento operatório nos
pacientes. Um desses métodos é o uso de drogas antiﬁbrinolíticas, entre as quais está o
ácido tranexâmico (ATX). O objetivo deste estudo foi veriﬁcar o uso dessa droga no controle
do  sangramento em cirurgias de escoliose idiopática.
Métodos: Estudo retrospectivo no qual foram analisados os prontuários de 40 pacientes sub-
metidos à artrodese toracolombar por via posterior. Desses, apenas 21 usaram o ATX e foram
relacionados no grupo teste. Os demais foram relacionados no grupo controle. Foram com-
paradas as médias de sangramento per e pós-operatório e a necessidade de hemotransfusão
entre os dois grupos.
Resultados: O grupo que usou o ATX teve sangramento peroperatório signiﬁcativamente
menor do que o grupo controle. Não houve diferenc¸a signiﬁcativa entre os grupos para o
sangramento pós-operatório e a necessidade de hemotransfusão.
Conclusões: O ATX foi eﬁcaz na reduc¸ão do sangramento peroperatório, conforme
demostrado em outros estudos. A correlac¸ão entre o seu uso e a reduc¸ão da necessidade
de  hemotransfusão é multifatorial e não pôde ser estabelecida neste trabalho. Acredita-
mos que o ácido tranexâmico possa ser um recurso útil e merece maior atenc¸ão em séries
prospectivas, duplo-cegas, randomizadas, com o devido controle das variáveis que inter-
ferem diretamente na perda sanguínea.
© 2015 Sociedade Brasileira de Ortopedia e Traumatologia. Publicado por Elsevier
Editora Ltda. Todos os direitos reservados.
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urgical correction of scoliosis involves signiﬁcant blood loss
f multifactorial origin. The duration of the surgical procedure,
he severity and type of the deformity, the technique used,
he mean perioperative arterial pressure and the hemostasis
trategies are among the variables that directly inﬂuence the
mount of bleeding.1–6
Within this scenario, the need for blood transfusions is a
eality that is of concern for surgeons and attracts the atten-
ion of researchers. Use of allogeneic blood with the aim of
aintaining tissue perfusion and preventing injuries to tar-
et organs in patients with large-volume blood losses is not
isk-free. Transmission of viral diseases, immunological reac-
ions and reductions in coagulation factors are known to be
omplications of blood transfusion.1,2,4
Given this situation, a variety of strategies have already
een proposed in attempts to diminish the dependence on
llogeneic blood in major surgery. These include storage of
utologous blood before the operation, normovolemic hemod-
lution, hypotensive anesthesia, use of a cell recovery machine
nd use of drugs with antiﬁbrinolytic properties, such as apro-
inin, epsilon-aminocaproic acid and tranexamic acid.6–10
Tranexamic acid is a synthetic antiﬁbrinolytic drug that has
he resultant effect of forming a reversible complex with plas-
inogen and plasmin. It inhibits ﬁbrinolysis, prevents lysis
f ﬁbrin coagulum and acts toward partial blocking of the
latelet aggregation induced by plasmin.11,12 Because of itslow cost and because its side effects are small, studies have
been conducted in different parts of the world in attempts to
evaluate its efﬁcacy for controlling perioperative bleeding in
major surgery.2,7–12
In our institution, tranexamic acid has recently been
used in operations to treat idiopathic scoliosis. The surgeons
counted on its efﬁcacy for reducing the bleeding consequent
to the surgical procedure, thus hoping to reduce the risk for
patients and to lead to lower need for blood transfusions.
The objective of this study was to document the inﬂuence
of tranexamic acid on the bleeding inherent to procedures for
treating idiopathic scoliosis with posterior instrumentation,
and to ascertain whether the expected reduction in bleeding
was capable of reducing the need for blood transfusion.
Methods
Proﬁle  of  the  sample
This was a retrospective cohort study on 40 patients who
underwent operations to correct idiopathic scoliosis between
December 2012 and March 2013. The study was approved by
the research ethics committee of the center where it was con-
ducted (CAAE-15734413.6.0000.5273).
The medical ﬁles of patients who underwent arthrodesis
via a posterior route with six or more  levels of arthrodesis,
whose bleeding consequent to the procedure was adequately
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Table 1 – Sample selection criteria.
Inclusion criteria
Age between 10 and 30 years
Body mass index between the 5th and 95th percentiles for the age
Idiopathic scoliosis
Posterior arthrodesis with fusion of six or more levels
Exclusion criteria
Mean perioperative arterial pressure exceeding 85 mmHg
Congenital or syndromic scoliosis
Table 2 – Proﬁles of the groups studied.
Control Tranexamic
acid
p-Value
Number of patients 19 21
Age (years) 21.6 ± 8.0 18.0 ± 4.4 0.1463
Weight (kg) 51.8 ± 5.9 55.5 ± 6.1 0.0628Previous spinal surgery
Use of the drug not in accordance with the standardized protocol
documented, were analyzed. We used the selection criteria
listed in Table 1.
Data  analyzed
Data that were considered relevant for the statistical analy-
ses were gathered from the medical ﬁles. These included: (1)
patient’s age; (2) patient’s weight at the time of the operation;
(3) duration of the procedure from the time of the skin incision
until its closure; (4) severity of the deformity; (5) bleeding doc-
umented in the medical ﬁle; and (6) use of blood transfusions.
The number of levels subjected to arthrodesis was used as
a variable for estimating the severity of the deformities.
The perioperative bleeding estimated in this study was
measured as the blood collected through the suction drains of
the surgical site during the operation plus the blood absorbed
in the surgical compressive dressings. For the calculations, the
density of human blood was taken to be 1.053 g/mL and the
quantity of saline solution used for irrigation of the surgical
site was discounted.
The postoperative bleeding was also taken into consider-
ation and was estimated from the output of the vacuum drains
that were installed subcutaneously over the ﬁrst 24 h after the
operation.
Surgical  technique
Three teams participated in the operations on the patients
selected. Basically, the surgical technique involved a skin inci-
sion on the midline above the spinal processes, followed by
dissection of the soft tissues until achieving exposure of the
vertebrae. Careful hemostasis was undertaken. The ligaments
and facets were released in order to gain spinal mobility, and
pedicle screws and pins were used to enable correction and
stabilization of the deformity. Autologous grafts coming from
the spinal processes and iliac crest were used to enable ver-
tebral fusion. Vacuum suction drains were positioned in the
subcutaneous layer in order to allow adequate drainage of the
surgical wound during the postoperative period.
Use  of  the  drug
In our institution, we  follow a protocol in which tranexamic
acid is used at an attack dose of 100 mg/kg of body weight,
administered over the 30-minute period prior to making the
skin incision. A maximum dose of 2 g of the drug is observed.
After the incision has been made, continual infusion is main-
tained at the rate of 30 mg/kg/h until the end of the procedure,Number of levels fused 9.2 ± 2.3 9.4 ± 2.2 0.7624
Duration of operation (h) 4.3 ± 1.4 4.0 ± 1.2 0.5291
i.e. when the skin has been closed. This protocol has already
been used safely in other centers.2,13
Division  of  the  groups
Among the 40 patients selected, 21 received tranexamic acid
in accordance with the administration protocol (test group),
while the other 19 were operated without receiving the drug
(control group).
Evaluation  of  complications
The patients involved in the study remained in hospital for an
average of ﬁve days after the operation. After this period, they
started to undergo periodic outpatient follow-ups. A search
was made in the medical ﬁles of the patients who  received
tranexamic acid with the aim of identifying any possible com-
plications relating to use of the drug, especially those resulting
from thromboembolic events, including venous thrombosis,
pulmonary embolism, arterial occlusion, kidney failure, etc.
Statistical  analysis
The results were expressed as means ± SD (standard devia-
tion). For comparisons, Student’s t test or the Mann–Whitney
test was used, when appropriate. Correlations between the
study variables were determined using the Spearman or
Pearson correlation coefﬁcient. The nominal variables were
evaluated using the Chi-square test. Results were accepted
as statistically signiﬁcant with p < 0.05. The statistical anal-
yses were performed using the Stata 11.2 software (StataCorp,
Texas, USA).
Results
Comparison  between  the  test  group  (tranexamic  acid)  and
the control  group
Overall, the groups studied were comparable and there was
no signiﬁcant difference between them regarding age, body
weight, number of levels subjected to arthrodesis and duration
of the operation (Table 2).
Mean  blood  loss
The mean perioperative blood loss among the patients who
received tranexamic acid was 747.6 ± 265.9 mL.  In the control
group, it was 996 ± 342.0 mL,  with a statistically signiﬁcant dif-
ference (p = 0.01) (Table 3).
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Table 3 – Mean amount of bleeding in the groups
studied.
Control Tranexamic acid
Perioperative loss (mL) 996.0 ± 342.0 747.6 ± 265.9
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Table 4 – Percentage perioperative blood volume loss.
Control Tranexamic
acid
p-Value
Blood volume loss
(%)
27.6 ± 9.4 19.4 ± 7.0 0.0083
Number of levels
subjected to
9.2  ± 2.3 9.4 ± 2.2 0.7624
Postoperative loss (mL) 410.5 ± 215.2 349.8 ± 268.4
Total loss (mL) 1406.5 ± 372.1 1097.3 ± 323.9
In relation to postoperative bleeding, we observed that
he control group presented a mean bleeding level that was
0.7 mL  greater than that of the patients who received tranex-
mic acid. This difference was not statistically signiﬁcant.
ercentage  perioperative  blood  volume  loss
ince the blood volume of each individual is a variable link
irectly to body weight, the percentage perioperative blood
olume loss of each patient was estimated by taking the mean
olume of 70 mL  per kg of body weight. In this manner, an
ndex capable of correlating the volume of blood lost during
he operation with the estimated total blood volume could be
reated.
It was observed that the percentage perioperative blood
olume loss in the tranexamic acid group (mean of 19.4 ± 7%)
as signiﬁcantly lower than that of the control group (mean
f 27.6 ± 9.4%) (p = 0.008) (Fig. 1).
We also observed that there was a positive linear correla-
ion between the percentage perioperative blood volume loss
nd the duration of the operation, for both groups (r = 0.369;
 = 0.0191).
elationship  between  the  percentage  perioperative  blood
olume  loss  and  the  number  of  levels  subjected  to
rthrodesis  (loss/level)
nother important variable considered in analyzing the
esults was the number of levels subjected to arthrodesis.
atients with curves that are more  severe generally require
rocedures that encompass larger numbers of vertebrae. This
s directly reﬂected in the duration of the surgical procedure
nd the amount of perioperative bleeding. In view of this
eality, we created an index correlating the percentage periop-
rative blood volume loss and the number of levels subjected
o arthrodesis (loss/level).We observed that the tranexamic acid group had a signif-
cantly lower loss/level ratio than that of the control group
p = 0.01) (Table 4).
Control Tranexamic acid
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ig. 1 – Comparison between percentage blood volume
osses in the control and test groups.arthrodesis
Loss/level 3.2 ± 1.3 2.1 ± 0.6 0.0101
Relationship  between  the  percentage  perioperative  blood
volume  loss,  the  number  of  levels  subjected  to  arthrodesis
and the  duration  of  the  operation
Considering that the percentage perioperative blood volume
loss has direct relationships with the number of levels sub-
jected to arthrodesis and the duration of the operation, we
applied linear regression in order to analyze the relationship
between the use of tranexamic acid and the percentage peri-
operative blood volume loss, controlled for the number levels
subjected to arthrodesis and the duration of the operation.
We found that use of this drug reduced the percentage blood
volume loss by 7.1% (p = 0.001).
Need  for  blood  transfusion
In the control group, the mean blood volume transfused
was 176.3 ± 252.6 mL  per patient. In the test group, it was
111.1 ± 216.5 mL.  Blood transfusion was required for 47.4% of
the control group and 28.6% of the group that received the
drug, i.e. the drug reduced the need for transfusion by 18.8%.
The Chi-square test did not show any evidence capable of cor-
relating the use of the drug with this reduction, for a 95%
conﬁdence level (p = 0.220).
Complications  resulting  from  use  of  tranexamic  acid
During the postoperative follow-up period, there were no clin-
ical or surgical complications attributable to use of tranexamic
acid.
Discussion
Our results showed that the group that used tranexamic acid
had a lower mean level of perioperative bleeding. Other stud-
ies that have analyzed this relationship have obtained similar
results.2,8–14
The percentage perioperative blood volume loss provides
a closer representation of the systemic consequences result-
ing from blood loss than does direct analysis of the bleeding
in absolute values. This is because by correlating bleeding,
blood volume and body weight, data of greater reliability
regarding the impact of blood loss on patients’ homeostasis
are furnished. Our results showed that the group that used
tranexamic acid had lower percentage perioperative blood vol-
ume  loss and reproduced the ﬁndings of another retrospective
cohort study that used the same index.13
The postoperative loss was also lower in the group that
used tranexamic acid, but this difference was non-signiﬁcant.
p . 2 0 
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In our study, certain factors may explain these results. The
plasma half-life of this drug is relatively short (3.1 h) and
its effect cannot be guaranteed throughout the 24-h period
subsequent to the surgical procedure. Moreover, the chances
that the material discharged through the drain might have
also included seroma and other tissue degradation products
was not taken into consideration by the professionals who
measured the contents of the collection ﬂasks and, thus,
measurement bias may have occurred. Only one study has
demonstrated a signiﬁcant difference in postoperative bleed-
ing between groups that used this drug and groups that used
placebo.10
The reduction in the need for transfusion observed in the
group that used tranexamic acid was not signiﬁcant for the
number of patients involved. Although studies with different
designs have obtained similar results,2,8–11,13–23 we take the
view that the model of our study was not the most appropriate
one for analyzing this outcome. Furthermore, we  noted that
there was no standardization of the parameters used by surgi-
cal and anesthesia teams with regard to using homologous or
autologous blood. Use of mean arterial pressure greater than
85 mmHg  as an exclusion criterion may not have been sufﬁ-
cient to neutralize the inﬂuence of higher blood pressure levels
on perioperative bleeding. We believe that keeping mean arte-
rial pressure within a band would be more  appropriate for
controlling the impact of this variable on blood loss, as has
been shown in some published series.3–5,24–26 The technical
skill of each surgeon with regard to controlling hemostasis and
the pedicular instrumentation is another important variable
that should be taken into consideration. This may have inter-
fered with the results between the groups, given that three
different teams operated on the patients studied.3,26
Since the risk of complications inherent to using homol-
ogous blood is directly proportional to the quantity of blood
used,27,28 the decrease in blood loss in the group that used
tranexamic acid should be valued. Moreover, the reduction in
perioperative blood loss may also diminish the risk of death,
but this is a theoretical proposition that has not been assessed
in any study.
The groups studied were statistically similar regarding age
group, body weight, during of the operation and severity of the
deformity, which diminished the interference of these vari-
ables in the study.3–5
The meta-analyses available still do not bring together
numbers capable of guaranteeing the safety of tranexamic
acid, for use in accordance with the protocol presented.25,27
In the present study, no complications were attributed to use
of tranexamic acid. The number of complications reported in
the literature so far has been very small and comparable with
those seen in using placebo,26–29 bit the seriousness of the pos-
sible thromboembolic events makes it essential to implement
regular follow-up for these patients.
The protocol for using tranexamic acid that was ana-
lyzed in the present study has already been applied by
other authors. Its efﬁcacy has been compared with placebo
and with other antiﬁbrinolytic drugs, and the results relat-
2,8,14,25,27ing to its efﬁcacy and safety have been promising.
Studies using tranexamic acid at lower doses have not
achieved the same proportional reduction in perioperative
bleeding.20,23
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Conclusion
Use of tranexamic acid is a low-cost, effective and safe
option for reducing perioperative bleeding during operations
to treat scoliosis with posterior instrumentation. Its efﬁcacy
in reducing the need for blood transfusion is a multifactorial
phenomenon that could not be demonstrated in the present
study.
Randomized prospective clinical studies with proper blind-
ing of the surgical and anesthesia teams thus become
necessary in order to evaluate the impact of tranexamic acid
on the need for blood transfusion and contribute toward ratio-
nalizing protocols so as to make them more  effective and safer
in using this drug.
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